Centauri Therapeutics, an immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X has provided an additional £3.8m in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in the ABX-01 programme into first in human clinical studies, bringing CARB-X’s total support since 2019 to £9.2m.
Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 2025. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the proprietary Alphamer platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound’s activity against Gram-negative bacteria.
